Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone
Journal article, Peer reviewed
MetadataShow full item record
Original versionSolli KK, Opheim A, Latif HL, Krajci P, Saltyte Benth J, Kunoe, Tanum L. Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone. Addiction. 2020 https://doi.org/10.1111/add.15378
Background and aim: Extended-release naltrexone (XR-NTX) is an underused treatment option for opioid dependence, today only available in a few countries in the world. Although effective, safe and feasible in short-term treatment, long-term data are scarce and there is no recommendation for required treatment length. The aims of the study were to determine the perceived need of long-term XR-NTX treatment and to examine long-term treatment outcomes. Design: In this prospective cohort study, following a parent 1-year study of XR-NTX, participants received treatment with XR-NTX at their own discretion for a maximum of 104 weeks. Setting: Five urban, outpatient addiction clinics in Norway. Participants: Opioid-dependent adults 18-60 years old (n=50) already participating in the parent study. Intervention: XR-NTX administrated as intra-muscular injections (380 mg) every 4 weeks. Measurements: Time in the study, use of opioids and other illicit substances, opioid craving, and treatment satisfaction reported every 4 weeks. Findings: Among 58 participants who completed the 1-year parent study, 50 chose to continue the treatment with XR-NTX. Median prolonged treatment time was 44.0 weeks (95% CI: 25.5-62.5), ranging from 8 to 104 weeks. Most participants (35, 70%) reported no relapse to opioid use during treatment while a subgroup (15, 30%) reported relapses to opioids during the study. Scores for mean treatment satisfaction and recommending treatment to others were very high (>9) and mean opioid craving score was very low (<1) on a scale ranging from 0 to 10. Conclusions: Extended-release naltrexone (XR-NTX) was well tolerated in long-term treatment of opioid dependent individuals in Norway already in XR-NTX treatment. On average, the participants chose to continue treatment for almost 1 year beyond the initial 9 to 12 months of treatment. Participants reported high treatment satisfaction and 70% showed no relapse to opioids during the treatment period.
Except where otherwise noted, this item's license is described as Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License
Showing items related by title, author, creator and subject.
Fecal microbiota profiles in treatment-naive pediatric inflammatory bowel disease ? associations with disease phenotype, treatment, and outcome Olbjørn, Christine; Småstuen, Milada Cvancarova; Thiis-Evensen, Espen; Nakstad, Britt; Vatn, Morten H; Jahnsen, Jørgen; Ricanek, Petr; Vatn, Simen Svendsen; Moen, Aina Elisabeth Fossum; Tannæs, Tone Møller; Lindstrøm, Jonas Christoffer; Söderholm, Johan D.; Halfvarson, Jonas; Gomollón, Fernando; Casén, Christina; Karlsson, Magdalena Kauczynska; Kalla, Rahul; Adams, Alex T.; Satsangi, Jack; Perminow, Gøri Margrete (Clinical and Experimental Gastroenterology;Volume 12, Journal article; Peer reviewed, 2019-12-13)Purpose: Imbalance in the microbiota, dysbiosis, has been identified in inflammatory bowel disease (IBD). We explored the fecal microbiota in pediatric patients with treatment-naïve IBD, non-IBD patients with gastrointestinal ...
Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs Midgard, Håvard; Finbråten, Ane-Kristine; Malme, K.B.; Berg-Pedersen, Riikka Mari; Tanum, Lars Håkon Reiestad; Inge Christoffer, Olsen; Bjørnestad, Ronny; Dalgard, Olav (Trials;21, Article number: 524 (2020), Journal article; Peer reviewed, 2020-06-15)Background: Scaled-up direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) infection among people who inject drugs (PWID) is crucial to reach the World Health Organization HCV elimination targets within 2030. ...
Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach Joranger, Pål; Nesbakken, Arild; Sorbye, Halfdan; Hoff, Geir; Oshaug, Arne; Aas, Eline (European Journal of Health Economics;, Journal article; Peer reviewed, 2019-11-09)New and emerging advances in colorectal cancer (CRC) treatment combined with limited healthcare resources highlight the need for detailed decision-analytic models to evaluate costs, survival and quality-adjusted life years. ...